Plasmacure closed a series A round of funding. The funding was raised with private investors, NextGen Ventures and East Netherlands Development Agency – Oost NL. NextGen Ventures is a fund built primarily on investments by the healthcare insurers Menzis and Friesland Zorgverzekeraar.
Plasmacure will use the investment to get CE mark and introduce the product to the market. The first focus is on diabetic foot wounds. This funding will support Plasmacure in developing the device for home use, and for treating other types of wounds.
“This funding is very important for us, because it will enable us to bring the cold plasma device to the market, to the people, who need it and for whom there is no real help at this moment. We realize that we can really start helping these people and this feels great” – said the CEO and founder of the company, Bas Zeper.
The primary reason for Oost NL to invest in Plasmacure is that it makes healthcare more affordable. Treating persistently open wounds costs the Dutch healthcare budget €2 billion. Pieter Rhemrev, manager of the business unit Capital at Oost NL, says, “The PLASOMA cold plasma system is handy, takes very little time to apply and is well tolerated. It clearly advances the quality of life for the patient. With this investment we are promoting result-oriented healthcare”.